Biomea’s Oral GLP-1 Candidate BMF-650 Shows Early Weight Loss

On October 13, 2026, Biomea Fusion reported topline results from the Phase 1 GLP-131 trial (NCT07223216) evaluating BMF-650, an investigational oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for obesity. In outpatient cohorts, mean weight reduction at Day 29 ranged from 1.5% to 3.2%, compared with 0.1% for pooled placebo. An additional cohort evaluating rapid dose escalation reported a larger reduction, although its small placebo group and unusual eating behavior complicate interpretation.

The findings provide an early assessment of BMF-650’s weight-loss activity and gastrointestinal tolerability. However, the four-week treatment period and limited dataset do not establish sustained efficacy, long-term safety or the suitability of starting treatment without dose escalation.

Phase 1 GLP-131 Study Design

GLP-131 was a randomized, double-blind, placebo-controlled Phase 1 study comprising a single ascending dose component followed by five multiple ascending dose (MAD) cohorts. Safety and tolerability were the co-primary endpoints, while pharmacokinetics, pharmacodynamics and weight reduction were secondary endpoints.

Cohorts 1–4 were conducted in an outpatient setting. Cohort 5 was subsequently added to evaluate a faster dosing schedule, with participants receiving 200 mg once daily for one week followed by 400 mg once daily for three weeks under confinement.

This additional cohort examined whether BMF-650 could reach the higher dose with fewer titration steps while maintaining tolerability.

Outpatient Cohorts Show Early Weight Reduction

Across Cohorts 1–4, mean weight reduction at Day 29 ranged from 1.5% to 3.2%, compared with 0.1% for pooled placebo. At doses of 200 mg once daily or higher, mean weekly weight reduction was approximately 0.97 kg.

Biomea did not provide a complete breakdown of these results by individual dose level in its topline announcement. Consequently, the findings do not establish a dose-response relationship or identify the optimal dose.

The outpatient results provide an initial signal of weight-loss activity, but their clinical significance requires evaluation in larger, longer-duration studies.

Confined Cohort Requires Separate Interpretation

Cohort 5 reported a mean weight reduction of 6.1%, equivalent to approximately 6.2 kg, at Day 29. The reduction was approximately 1.55 kg per week, with no reported attenuation during treatment.

However, the two placebo participants lost a similar amount of weight. Although participants were offered 2,100 kcal per day, the placebo participants consumed only about one-third of the food provided. Biomea suggested that confinement may have influenced eating behavior and recommended interpreting this cohort separately from the outpatient cohorts.

These observations limit the ability to estimate BMF-650’s treatment effect relative to placebo in Cohort 5. The larger reduction should therefore not be interpreted as evidence of superior efficacy over the outpatient regimens.

Four-Week Safety and Tolerability Findings

Across 40 BMF-650-treated participants in the five active-dose cohorts, all reported treatment-emergent adverse events (TEAEs) were mild or moderate. No severe or serious TEAEs occurred, and no participant required a TEAE-related dose modification or discontinued the study because of an adverse event.

Nausea occurred in 17.5% of participants, vomiting in 7.5%, constipation in 10% and diarrhea in 5%. No adverse events involving increased alanine aminotransferase (ALT) or aspartate aminotransferase (AST) were reported.

In Cohort 5, nausea and vomiting each occurred in one of eight treated participants, while constipation occurred in two. No diarrhea was reported, and all gastrointestinal events in this cohort were Grade 1.

These findings suggest that rapid escalation was tolerated over four weeks in this small cohort. They do not establish long-term safety or exclude less common adverse events.

 Pharmacokinetics and the Dose-Escalation Strategy

Biomea reported sustained systemic exposure and a low peak-to-trough ratio, findings that support further evaluation of once-daily oral dosing.

Participants in Cohort 5 tolerated escalation from 200 mg to 400 mg after one week, with gastrointestinal tolerability described as comparable to that observed with slower titration schedules. The company believes this approach could support investigation of a regimen requiring fewer titration steps, potentially including a no-titration strategy.

However, Cohort 5 did not test starting treatment directly at 400 mg. Whether a true no-titration regimen can maintain tolerability requires prospective evaluation.

Development Outlook and Clinical Implications

BMF-650 remains investigational. Biomea said further development will require longer-term toxicology studies and that it is positioning the program for a potential strategic partnership, including a possible licensing arrangement for late-stage development and commercialization. A fuller analysis of the clinical findings is planned for a future medical meeting.

The company’s broader development focus remains icovamenib, a menin inhibitor being investigated in type 1 and type 2 diabetes.

BMF-650 was designed to limit acute gastrointestinal receptor activation while maintaining systemic exposure. The Phase 1 findings provide preliminary clinical observations relevant to that strategy, but they do not establish that the approach separates weight-loss activity from gastrointestinal adverse effects.

The key question for further development is whether BMF-650 can sustain weight reduction with acceptable tolerability while reducing the need for gradual dose escalation. Longer-duration studies will be needed to establish the durability of weight loss, characterize safety and determine whether a simplified dosing regimen is feasible.

Reference

 Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, Biomea Fusion, 13 October 2026

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants, ClinicalTrials.gov ID NCT07223216